Jove
Visualize
Contact Us

Related Experiment Videos

Mycophenolate mofetil: a promising immunosuppressive agent.

A A Kulkarni1, Bharat V Shah

  • 1Department of Medicine and Section of Nephrology, Mumbai 400 016, India.

The Journal of the Association of Physicians of India
|January 7, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of kidney and liver exchange transplantation in India (2000-2025): a multicentre, retrospective cohort study.

The Lancet regional health. Southeast Asia·2025
Same author

A Preemptive Living Donor Renal Transplant in an HIV Positive Patient from an HIV Positive Donor.

Indian journal of nephrology·2022
Same author

An Unusual Presentation of Multiple Myeloma.

Indian journal of nephrology·2022
Same author

Retrospective Diagnosis of Nail-patella Syndrome.

Indian journal of nephrology·2021
Same author

Evidence of the Effectiveness of Pictorial Health Warnings on Cigarette Packaging in Nepal.

Asian Pacific journal of cancer prevention : APJCP·2021
Same author

Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients.

ESMO open·2021
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Mycophenolate mofetil is a new immunosuppressant reducing acute graft rejection. It also treats autoimmune diseases and glomerulopathies, with mainly gastrointestinal side effects.

Area of Science:

  • Immunology
  • Pharmacology
  • Nephrology

Background:

  • Advancements in immunosuppressive agents have reduced acute graft rejection rates.
  • Mycophenolate mofetil is a novel immunosuppressant now available in India.
  • This drug has demonstrated efficacy in transplantation and autoimmune conditions.

Purpose of the Study:

  • To evaluate the efficacy of Mycophenolate mofetil in preventing and treating graft rejection.
  • To assess its utility in managing glomerulopathies and other autoimmune diseases.
  • To document the safety profile and common side effects of Mycophenolate mofetil.

Main Methods:

  • Clinical studies assessing Mycophenolate mofetil in transplant recipients.
  • Application of the drug in patients with primary and secondary glomerulopathies, including Systemic Lupus Erythematosus (SLE).

Related Experiment Videos

  • Monitoring of patient outcomes and adverse events, particularly gastrointestinal disturbances.

    • Main Results:

    • Mycophenolate mofetil effectively prevents and treats acute and chronic graft rejection.
    • Successful application in managing glomerulopathies and autoimmune diseases like SLE.
    • The drug is generally well-tolerated, with gastrointestinal issues being the primary side effect.

    Conclusions:

    • Mycophenolate mofetil is a valuable therapeutic option for post-transplant rejection.
    • Its use extends to treating various autoimmune conditions and kidney diseases.
    • The favorable side effect profile supports its clinical utility.